Oncology and Hematology - Global Oncology Academy

497-512 of 789

Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CE
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
0.25 credits
0.25 credits
Exercise in Multiple Myeloma: Balancing Benefits and Safety
Exercise in Multiple Myeloma: Balancing Benefits and Safety
Project Oncology®
Exercise in Multiple Myeloma: Balancing Benefits and Safety
Jens Hillengass, MD, PhD
- Jens Hillengass, MD, PhD
Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
On the Frontlines of Prostate Cancer
Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
Neal Shore, MD, FACS
- Neal Shore, MD, FACS
mCRPC Care: Predicting Outcomes with a Novel Cell-Free DNA Sequencing Assay
mCRPC Care: Predicting Outcomes with a Novel Cell-Free DNA Sequencing Assay
Global Oncology Academy
mCRPC Care: Predicting Outcomes with a Novel Cell-Free DNA Sequencing Assay
Scott Dehm, PhD
- Scott Dehm, PhD
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Project Oncology®
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Global Oncology Academy
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Project Oncology®
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Adrienne Waks, MD
- Adrienne Waks, MD
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Sara Lonardi, MD
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Sara Lonardi, MD
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
MinuteCE®
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
Sara Lonardi, MD
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Expert Viewpoint: Optimizing Breast Cancer Treatment
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
William J. Gradishar, MD; Erica L. Mayer, MD, MPH
1.50 program credits
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
MinuteCE®
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
Sara Lonardi, MD; Aparna R. Parikh, MD
1.25 program credits
- Sara Lonardi, MD
- Aparna R. Parikh, MD
- Alan Venook, MD
1.25 program credits
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Alan Venook, MD
1.25 program credits
- Alan Venook, MD
1.25 program credits
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Erica L. Mayer, MD, MPH
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits

32/11